Aktuelt

Behandling af svær overvægt og type 2 diabetes baseret på inkretinhormon

Danish Medical Journal har inviteret professor Jens Juul Holst til at skrive et state-of-the-art review om sin forskning i fedme og type 2 diabetes, især med henblik på opklaringen af hormonale forstyrrelser og mulighederne for behandling baseret på hormoner. Dette review er en del af artikelserien i DMJ, hvor vi hylder aktive nordiske forskere som har et H-indeks på 100 eller derover.

Professor Jens Juul Holst (foto Lars Svankjær Videnskabernes Selskab)

12. jan. 2023

1 min.

ABSTRACT: Recent studies show that incretin hormone analogues effectively control blood glucose while producing major weight losses and reducing the risk of all-cause mortality, myocardial infarction, stroke and kidney function impairment. Furthermore, the risk of dementia and cognitive impairment is reduced. A monomolecular coagonist (tirzepatide) of receptors for both incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide) produced HbA1c values below 5.7% in 50% of the treated patients and weight losses exceeding 20% in obese individuals. These new agents will radically change our approach to the treatment of T2DM and obesity alike.

Læs invited state-of-the-art review i Danish Medical Journal

Incretin-based therapy of metabolic disease af Professor Jens Juul Holst